Abstract
The in vitro evaluation of a series of (hetero)aromatic-substituted 4-hydroxycyclohexa-2,5-dienones (quinols) and analogues against M. tuberculosis is reported. The most active compound in the series was found to be 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dienone 1a with a minimum inhibitory concentration of 0.78 μg/mL. Biochemical evidence for involvement of the small redox protein thioredoxin C - a novel drug target - is also presented.
Keywords: Antitubercular activity, Mycobacterium tuberculosis (MTb), quinols, thioredoxin
Letters in Drug Design & Discovery
Title: Antitubercular Properties of Substituted Hydroxycyclohexadienones
Volume: 3 Issue: 6
Author(s): Manish Shah, Geoffrey Wells, Tracey D. Bradshaw, Charles A. Laughton, Malcolm F.G. Stevens and Andrew D. Westwell
Affiliation:
Keywords: Antitubercular activity, Mycobacterium tuberculosis (MTb), quinols, thioredoxin
Abstract: The in vitro evaluation of a series of (hetero)aromatic-substituted 4-hydroxycyclohexa-2,5-dienones (quinols) and analogues against M. tuberculosis is reported. The most active compound in the series was found to be 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dienone 1a with a minimum inhibitory concentration of 0.78 μg/mL. Biochemical evidence for involvement of the small redox protein thioredoxin C - a novel drug target - is also presented.
Export Options
About this article
Cite this article as:
Shah Manish, Wells Geoffrey, Bradshaw D. Tracey, Laughton A. Charles, Stevens F.G. Malcolm and Westwell D. Andrew, Antitubercular Properties of Substituted Hydroxycyclohexadienones, Letters in Drug Design & Discovery 2006; 3 (6) . https://dx.doi.org/10.2174/157018006777805486
DOI https://dx.doi.org/10.2174/157018006777805486 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Structure- and Ligand-Based Structure-Activity Relationships for a Series of Inhibitors of Aldolase
Current Computer-Aided Drug Design Editorial: Challenge for the European Union: Immigrant and Refugee Health
Inflammation & Allergy - Drug Targets (Discontinued) Leptin as a Novel Therapeutic Target for Immune Intervention
Current Drug Targets - Inflammation & Allergy Editorial (Thematic Issue: Medicinal Chemistry Studies of Neglected Diseases)
Mini-Reviews in Medicinal Chemistry Solubility and Permeability Measurement and Applications in Drug Discovery
Combinatorial Chemistry & High Throughput Screening Cytochrome P450s: Mechanisms and Biological Implications in Drug Metabolism and its Interaction with Oxidative Stress
Current Drug Metabolism A Rational Approach to Identify Inhibitors of Mycobacterium tuberculosis Enoyl Acyl Carrier Protein Reductase
Current Pharmaceutical Design A Scientometrics Analysis and Visualization of Depressive Disorder
Current Neuropharmacology Clostridium difficile Infection in Children with Inflammatory Bowel Disease: Current Evidence
Current Pharmaceutical Design iMTBGO: An Algorithm for Integrating Metabolic Networks with Transcriptomes Based on Gene Ontology Analysis
Current Genomics The Physiology of Nitric Oxide: Control and Consequences
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews Editorial [ Carbonic Anhydrases as Drug Targets Executive Editor: Claudiu T. Supuran ]
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Infective Drug Discovery Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design Targeting the Methyl Erythritol Phosphate (MEP) Pathway for Novel Antimalarial, Antibacterial and Herbicidal Drug Discovery: Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) Enzyme
Current Pharmaceutical Design Extrapulmonary Sarcoidosis: A Chameleon Disease at Imaging
Current Medical Imaging Potential Crossreactivity of Human Immune Responses Against HCMV Glycoprotein B
Current Drug Discovery Technologies Venom Peptide Modulators of the Immune System
Inflammation & Allergy - Drug Targets (Discontinued) Adverse Drug Reactions to Anti-TB Drugs: Pharmacogenomics Perspective for Identification of Host Genetic Markers
Current Drug Metabolism